OakChart

Personalis Inc

PSNLHealthcare·Diagnostics & Research·USA·Small·NASD·Nov 11 • 2:14 PM ET

15.96+0.08 (0.49%)
2026-11-11 20:14 CET
Market cap
1,721.46 USD m
Revenue, TTM
80.77 USD m
Net income, TTM
-119.33 USD m
Free cash flow, TTM
-107.69 USD m
EPS diluted, TTM
-1.16
P/E
-
Compare

Price

PSNL against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.007.1M14.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PSNLclose 15.9620-day 15.8550-day 16.12200-day 11.5215.9652w high52w low

15.5% under the 52-week high of 18.89 on 21 Aug 2026. 52-week low 4.96 on 29 Apr 2026. Last 15 sessions, 3.9% high to low

Profile

PSNL
52-week range, 79% of the way up
4.9518.89

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

IndexRUT
Employees260
IPOJun 20, 2019
Beta2.36
ATR, 14d0.29
Rel volume0.38
Short float9.24%
Insider own32.64%
Inst own63.08%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.73B
Enterprise Value1.58B
Income-119.33M
Sales80.77M
Book/sh1.96
Cash/sh1.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees260
IPOJun 20, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S21.42
P/B8.13
P/C9.08
P/FCF-
EV/EBITDA-
EV/Sales19.52
Quick Ratio4.38
Current Ratio4.51
Debt/Eq0.17
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.16
EPS next Y-1.00
EPS next Q-0.24
EPS this Y-22.42%
EPS next Y10.29%
EPS next 5Y4.57%
EPS past 3/5Y28.38% 2.91%
Sales past 3/5Y2.30% -2.40%
EPS Y/Y TTM-32.64%
Sales Y/Y TTM16.88%
EPS Q/Q-29.17%
Sales Q/Q76.59%
EarningsNov 04 AMC
EPS/Sales Surpr.-21.53% 18.82%

Ownership

Insider Own32.64%
Insider Trans-1.61%
Inst Own63.08%
Inst Trans0.77%
ROA-44.66%
ROE-62.14%
ROIC-49.32%
Gross Margin16.71%
Oper. Margin-156.66%
Profit Margin-147.74%
SMA200.68%
SMA50-0.98%
SMA20038.59%
Trades-

Technical

Shs Outstand108.38M
Shs Float73.02M
Short Float9.24%
Short Ratio2.50
Short Interest6.75M
52W High18.89 -15.52%
52W Low4.95 222.07%
Volatility1.63% 1.67%
ATR (14)0.29
RSI (14)52.01
Beta2.36
Rel Volume0.38
Avg Volume2.70M
Volume768,748

Performance

Perf Week1.07%
Perf Month0.68%
Perf Quarter10.67%
Perf Half Y149.74%
Perf YTD100.48%
Perf Year89.08%
Perf 3Y1464.55%
Perf 5Y-15.92%
Perf 10Y-
Recom3.00
Target Price16.25
Prev Close15.88
Price15.96
Change %0.49%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 06, 2026DowngradeBBTIG ResearchBuy → Neutral
Aug 24, 2026DowngradeCCraig HallumBuy → Hold$16.25+1.8%
Dec 02, 2025ResumedMMorgan StanleyEqual-Weight$11-31.1%
May 15, 2025InitiatedGGuggenheimBuy$6-62.4%
Mar 17, 2025InitiatedCCraig HallumBuy$8-49.9%
Feb 06, 2023UpgradeNNeedhamHold → Buy$8-49.9%
Feb 06, 2023UpgradeNNeedhamHold → Buy
Jan 07, 2022UpgradeBBofA SecuritiesNeutral → Buy$27 → $23+44.1%
Nov 05, 2021DowngradeMMorgan StanleyOverweight → Equal-Weight
Nov 03, 2021DowngradeNNeedhamBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
NTRANatera Inc46.27B
GHGuardant Health Inc21.10B
NEONeogenomics Inc2.19B
ADPTAdaptive Biotechnologies Corp5.00B
VCYTVeracyte Inc2.05B
TEMTempus AI Inc14.64B
BLLNBilliontoone Inc5.26B
GRALGRAIL Inc5.65B
FLGTFulgent Genetics Inc716.08M
CAICaris Life Sciences Inc6.95B

Insider trading

latest 14 of 47
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hall Christopher MChief Executive OfficerNov 03 '26Sale15.8729,112462,007199,415Nov 04 04:15 PM
Moore Stephen MichaelSVP and Chief Legal OfficerSep 18 '26Sale16.222,06833,54390,257Sep 22 04:10 PM
Chen RichardPresident and CMOSep 18 '26Sale16.223,99864,848169,882Sep 22 04:10 PM
Hall Christopher MChief Executive OfficerSep 18 '26Sale16.227,459120,985228,527Sep 22 04:10 PM
Tachibana AaronCFO AND COOSep 18 '26Sale16.222,93147,541195,902Sep 22 04:10 PM
Chen RichardPresident and CMOJul 15 '26Option Exercise2.44100,000244,000273,880Jul 15 09:27 PM
Chen RichardPresident and CMOJul 15 '26Sale15.15100,0001,515,000173,880Jul 15 09:27 PM
RICHARD CHENOfficerJul 15 '26Proposed Sale15.03100,0001,503,000Jul 15 04:24 PM
Hall Christopher MChief Executive OfficerJul 09 '26Option Exercise1.61100,000161,000335,986Jul 09 08:46 PM
Hall Christopher MChief Executive OfficerJul 09 '26Sale15.08100,0001,508,000235,986Jul 09 08:46 PM
Chris HallDirectorJul 09 '26Proposed Sale14.11100,0001,411,000Jul 09 04:26 PM
Tachibana AaronCFO AND COOJun 29 '26Option Exercise5.324,98226,504203,815Jun 29 05:50 PM
Tachibana AaronCFO AND COOJun 29 '26Sale14.004,98269,748198,833Jun 29 05:50 PM
AARON TACHIBANAOfficerJun 29 '26Proposed Sale13.024,98264,866Jun 29 04:44 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.320-0.263-0.32025.6021.543
2026Q22026-08-04-0.300-0.263-0.30122.3616.696
2026Q12026-05-07-0.290-0.271-0.28815.4714.497
2025Q42026-02-26-0.260-0.288-0.25817.3517.057
2025Q32025-11-04-0.240-0.267-0.24414.5013.718
2025Q22025-08-05-0.230-0.240-0.22717.2020.118
2025Q12025-05-06-0.180-0.247-0.18020.6117.417
2024Q42025-02-27-0.230-0.283-0.22516.8016.806
2024Q32024-11-06-0.640-0.350-0.64025.7121.336
2024Q22024-08-07-0.240-0.373-0.24422.5819.276
2024Q12024-05-08-0.260-0.407-0.25619.5318.376
2023Q42024-02-28-0.540-0.500-0.53619.6819.635
2023Q32023-11-07-0.600-0.519-0.59818.2516.986
2023Q22023-08-08-0.500-0.536-0.50316.7016.496
2023Q12023-05-03-0.610-0.583-0.61318.8617.356
2022Q42023-02-23-0.670-0.645-0.67216.7216.725

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.390-0.990-0.80365.2164.89
2020FY-1.200-1.133-1.05678.6578.43
2021FY-1.490-1.530-1.48685.4985.32
2022FY-2.480-2.454-2.47965.0565.05
2023FY-2.250-2.212-2.24873.4873.42
2024FY-1.370-1.448-1.37284.6184.60
2025FY-0.910-0.939-0.91069.6569.53
2026FY--1.114--85.47
2027FY--1.000--111.06
2028FY--0.791--155.4
2029FY--0.580--184.1
2030FY--0.470--227.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0941025.2923.6726.70
2026Q4S2026-11-0541025.3023.7026.70
2026Q4S2026-11-0440024.9723.7026.56
2026Q4S2026-10-1940024.9723.7026.56
2026Q4S2026-10-0540124.9723.7026.56
2026Q4S2026-08-2140124.9723.7026.56
2026Q4S2026-08-1940124.9723.7026.56
2026Q4S2026-08-1640124.9723.7026.56
2026Q4S2026-08-0550124.7723.7026.56
2026Q4S2026-07-2850024.9524.0026.56
2026Q4S2026-07-2250124.9524.0026.56
2026Q4S2026-07-1751224.9524.0026.56
2026Q4S2026-07-1462224.6423.1026.56
2026Q4S2026-05-1462224.6323.0026.56

Estimate history

EPS, annual-0.763-0.643-0.803-1.056-1.486-2.479-2.248-1.372-0.911-1.1621
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.64-0.225-0.18-0.227-0.244-0.258-0.288-0.301-0.315
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual9.39337.77465.20778.64885.49465.04773.48184.61469.64880.77
Period201720182019202020212022202320242025TTM
Sales, quarterly25.70916.820.60517.20314.49517.34515.47222.35725.596
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual30.93930.93931.24339.10644.90546.70750.48185.171102.476108.378
Period201720182019202020212022202320242025MRQ
Shares, quarterly70.63885.17188.31988.6588.745102.476104.692106.367108.378
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue80.7769.6584.6173.4865.0585.4978.6565.2137.77
Cost of Goods Sold Incl. D&A67.2853.8757.7955.2751.7053.8458.5343.1325.97
Gross Profit13.4915.7826.8218.2113.3531.6620.1122.0811.80
Selling, General and Administrative Excl. Other140.03103.8395.09114.50128.8897.0162.2644.5025.57
Research and Development60.0250.2648.9164.7864.9149.3128.5722.4214.30
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-126.54-88.06-68.27-96.29-115.53-65.35-42.15-22.42-13.77
Interest Expense0.180.200.020.110.200.180.001.131.89
Unusual Expense0.000.000.0013.640.000.000.003.114.47
Net Income Before Taxes-119.30-81.25-81.27-108.21-113.28-65.21-41.22-25.07-19.88
Income Taxes0.030.020.020.080.040.010.060.010.01
Consolidated Net Income-119.33-81.27-81.28-108.30-113.31-65.23-41.28-25.08-19.89
Net Income From Continuing Operations-119.33-81.27-81.28-108.30-113.31-65.23-41.28-25.08-19.89
Net Income-119.33-81.27-81.28-108.30-113.31-65.23-41.28-25.08-19.89
EPS (Recurring)-1.11-0.91-1.37-2.05-2.48-1.49-1.06-0.73-0.54
EPS (Basic, Before Extraordinaries)-1.16-0.91-1.37-2.25-2.48-1.49-1.06-0.80-0.64
EPS (Diluted)-1.16-0.91-1.37-2.25-2.48-1.49-1.06-0.80-0.64
EBITDA-116.81-78.01-57.33-85.00-102.65-56.39-34.98-16.69-10.70
Non-Operating Income (Expense)7.437.01-12.971.832.460.330.931.580.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.807.458.4411.1015.3511.366.013.550.96
Price To Sales Ratio21.6110.204.051.381.397.3318.205.22-
Gross Margin16.7122.6531.7024.7820.5237.0325.5733.8631.25
Operating Margin-156.66-126.43-80.68-131.05-177.61-76.44-53.59-34.38-36.45
Net Margin-147.74-116.69-96.06-147.38-174.20-76.29-52.49-38.47-52.64
Shares Outstanding108.38102.4885.1750.4846.7144.9039.1131.2430.94
Market Capitalization1,721.461,721.46410.50102.9791.02639.071,425.33340.45312.96

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue25.6022.3615.4717.3414.4917.2020.6116.80
Cost of Goods Sold Incl. D&A19.0317.6115.1915.4512.5812.4513.4012.25
Gross Profit6.574.740.281.901.914.767.214.55
Selling, General and Administrative Excl. Other42.0938.3332.4427.1725.2026.5624.9022.66
Research and Development16.0716.3414.5413.0712.1712.3812.6411.49
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-35.52-33.59-32.16-25.27-23.29-21.80-17.70-18.11
Interest Expense0.040.040.050.070.060.050.03-
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-33.80-31.68-30.02-23.80-21.65-20.05-15.74-16.42
Income Taxes0.000.010.020.010.000.000.010.00
Consolidated Net Income-33.80-31.68-30.03-23.81-21.65-20.06-15.75-16.43
Net Income From Continuing Operations-33.80-31.68-30.03-23.81-21.65-20.06-15.75-16.43
Net Income-33.80-31.68-30.03-23.81-21.65-20.06-15.75-16.43
EPS (Recurring)-0.32-0.30-0.29-0.26-0.24-0.23-0.18-0.23
EPS (Basic, Before Extraordinaries)-0.32-0.30-0.29-0.26-0.24-0.23-0.18-0.23
EPS (Diluted)-0.32-0.30-0.29-0.26-0.24-0.23-0.18-0.23
EBITDA-33.04-31.18-29.79-22.80-20.82-19.27-15.11-15.57
Non-Operating Income (Expense)1.761.952.191.531.711.801.981.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.093.141.751.821.642.241.752.11
Price To Sales Ratio21.6120.2810.2910.558.377.233.584.98
Gross Margin25.6721.211.8210.9513.2027.6534.9827.08
Operating Margin-138.76-150.25-207.87-145.67-160.68-126.75-85.88-107.81
Net Margin-132.06-141.71-194.11-137.28-149.38-116.58-76.44-97.77
Shares Outstanding108.38106.37104.69102.4888.7588.6588.3285.17
Market Capitalization1,721.461,403.26666.51706.88578.17579.41309.80410.50

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments239.95185.01114.18167.66287.06203.29128.2919.7422.62
Short Term Receivables16.208.1417.7316.6418.476.353.304.461.94
Inventories5.263.985.666.384.082.671.422.130.82
Other Current Assets5.653.934.366.817.095.443.381.930.81
Total Current Assets267.06201.05141.93197.49316.70217.75136.4028.2626.18
Net Property, Plant & Equipment59.9364.7375.2288.4273.4722.1115.9511.456.34
Total Investments and Advances1.791.791.791.790.000.000.000.000.00
Other Assets5.382.706.165.006.354.984.941.961.04
Total Assets334.16270.27225.10292.70396.53244.84157.2941.6733.56
Short Term Debt Incl. Current Port. of LT Debt8.089.379.417.615.532.441.365.0017.51
Accounts Payable12.996.4014.9212.859.228.307.346.574.04
Income Tax Payable--0.040.120.120.100.210.180.11
Other Current Liabilities18.5615.3622.8712.5416.4429.8041.0546.1127.34
Total Current Liabilities39.6331.1347.2333.1331.3140.6449.9657.8548.99
Long Term Debt32.7334.9839.5541.4254.488.540.640.680.29
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.621.208.870.010.430.720.000.120.89
Total Liabilities72.9867.3195.6674.5686.2349.9050.6058.6550.17
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0089.4076.00
Common Equity261.19202.96129.44218.14310.30194.94106.69-106.39-92.60
Total Shareholders Equity261.19202.96129.44218.14310.30194.94106.69-16.98-16.61
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity261.19202.96129.44218.14310.30194.94106.69-16.98-16.61
Total Liabilities & Stockholders Equity334.16270.27225.10292.70396.53244.84157.2941.6733.56
Book Value Per Share2.552.382.564.676.914.993.41-3.44-2.99
Tangible Book Value Per Share2.552.382.564.676.914.993.41-3.44-2.99
Full-Time Employees260229225399326235182139-
Price to Book Ratio8.092.450.680.382.077.343.192.80-
Return on Assets-26.89-32.82-41.83-32.88-20.34-20.53-25.21-52.87-
Return on Equity-35.02-48.91-62.31-42.89-25.82-27.37-55.92--
Return on Invested Capital-27.65-34.16-64.08-43.66-17.88-20.29-23.37--
Quick Ratio6.616.332.885.779.985.292.700.450.52
Current Ratio6.746.463.005.9610.115.362.730.490.53

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-119.33-81.27-81.28-108.30-113.31-65.23-41.28-25.08-19.89
Depreciation9.7310.0510.9411.3012.888.967.175.733.07
Other Funds (Non Cash)9.456.4727.7927.2619.5916.588.698.556.97
Funds from Operations-100.15-64.75-42.56-69.74-80.84-39.68-25.42-10.81-9.85
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.58-10.19-2.5913.4810.61-31.14-17.23-7.2615.42
Cash from Operating Activities-97.57-74.95-45.15-56.26-70.23-70.83-42.65-18.075.57
Capital Expenditures-10.12-4.50-1.60-10.91-49.90-11.08-3.25-8.38-7.85
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.120.000.240.000.000.000.000.00-
Purchase or Sale of Investments11.79-18.06-33.7124.01102.43-48.99-61.90-73.200.00
Purchase of Investments-167.83-210.17-121.71-103.94-121.49-267.13-161.78-78.900.00
Sale Or Maturity of Investments179.61192.1188.00127.95223.92218.1499.885.700.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities1.78-22.57-35.0713.1052.54-60.07-65.14-81.58-7.85
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock148.09129.94117.0310.862.46166.39121.27141.220.05
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock148.09129.94117.0310.862.46166.39121.27141.220.05
Proceedsfrom Stock Options134.52126.8098.593.510.00161.92121.27140.51-0.02
Issuance or Reduction of Debt, Net-3.920.58-1.130.17-1.103.310.00-5.49-0.65
Change in Long Term Debt-3.920.58-1.130.17-1.103.310.00-5.49-0.65
Issuance of Long Term Debt0.002.590.003.441.195.170.0019.510.00
Reduction of Long Term Debt-3.92-2.00-1.13-3.26-2.29-1.860.00-25.00-0.65
Net Financing Active Other Cash Flow-0.08-0.19-1.230.000.000.000.00-0.790.00
Other Financing Activities Uses-0.08-0.19-1.230.000.000.000.00-0.790.00
Cash from Financing Activities144.08130.34114.6711.031.37169.70121.27134.95-0.59
Exchange Rate Effect-0.000.01-0.02-0.02-0.130.050.010.00-0.00
Net Change in Cash48.3032.8334.43-32.14-16.4638.8513.4835.30-2.87
Free Cash Flow-107.69-79.45-46.75-67.17-120.13-81.91-45.90-26.45-2.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments190.60212.66233.22239.95150.51173.23
Short Term Receivables18.0415.1013.0216.2014.389.95
Inventories6.477.755.255.263.734.56
Other Current Assets7.037.655.035.654.864.72
Total Current Assets222.13243.16256.52267.06173.47192.47
Net Property, Plant & Equipment65.0863.4363.4059.9362.2561.47
Total Investments and Advances1.791.791.791.791.791.79
Other Assets2.603.763.695.385.322.95
Total Assets291.60312.13325.39334.16242.84258.68
Short Term Debt Incl. Current Port. of LT Debt7.907.837.768.088.379.05
Accounts Payable14.4916.0012.6812.9911.159.93
Other Current Liabilities26.8822.5518.6118.5616.6412.75
Total Current Liabilities49.2746.3839.0539.6336.1631.72
Long Term Debt29.3030.1731.0232.7333.5034.22
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.360.420.560.621.771.91
Total Liabilities78.9376.9770.6372.9871.4267.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity212.67235.16254.76261.19171.41190.83
Total Shareholders Equity212.67235.16254.76261.19171.41190.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity212.67235.16254.76261.19171.41190.83
Total Liabilities & Stockholders Equity291.60312.13325.39334.16242.84258.68
Book Value Per Share1.962.212.432.551.932.15
Tangible Book Value Per Share1.962.212.432.551.932.15
Full-Time Employees---260--
Price to Book Ratio8.095.512.504.123.032.79
Return on Assets-44.66-37.55-31.92-26.89-30.61-41.12
Return on Equity-62.14-50.32-41.35-35.02-43.69-60.26
Return on Invested Capital-13.97-11.94-10.51-8.10-10.57-8.91
Quick Ratio4.385.086.446.614.695.92
Current Ratio4.515.246.576.744.806.07

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-33.80-31.68-30.03-23.81-21.65-20.06
Depreciation2.482.412.372.462.472.53
Other Funds (Non Cash)3.283.051.611.511.582.23
Funds from Operations-28.04-26.22-26.05-19.84-17.61-15.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.970.453.57-2.41-4.202.37
Cash from Operating Activities-27.07-25.77-22.48-22.25-21.80-12.94
Capital Expenditures-3.07-3.78-3.19-0.08-1.63-0.29
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.120.000.000.00
Purchase or Sale of Investments27.0841.95-42.94-14.3020.35-4.08
Purchase of Investments-19.91-27.16-67.04-53.73-48.15-44.02
Sale Or Maturity of Investments46.9969.1024.1039.4268.5039.94
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities24.0138.16-46.01-14.3818.72-4.37
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.458.1521.23111.260.090.67
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.458.1521.23111.260.090.67
Proceedsfrom Stock Options0.004.5520.95109.02-0.800.67
Issuance or Reduction of Debt, Net-0.08-0.16-3.40-0.28-0.41-1.00
Change in Long Term Debt-0.08-0.16-3.40-0.28-0.41-1.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.08-0.16-3.40-0.28-0.41-1.00
Net Financing Active Other Cash Flow0.000.000.00-0.080.000.00
Other Financing Activities Uses0.000.000.00-0.080.000.00
Cash from Financing Activities7.377.9917.83110.89-0.32-0.33
Exchange Rate Effect-0.01-0.010.010.00-0.000.01
Net Change in Cash4.3020.37-50.6574.27-3.40-17.63
Free Cash Flow-30.14-29.55-25.67-22.32-23.43-13.22

Revenue breakdown

United States2024: 84.61M 2025: 69.65M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.24%6.7M73.0M2.73M
2026-10-159.30%6.8M73.0M3.32M
2026-09-3011.71%8.4M72.0M3.69M
2026-09-1511.49%8.3M71.9M4.06M
2026-08-3111.65%8.4M71.9M4.16M
2026-08-1411.67%8.4M71.9M3.84M
2026-07-3112.11%8.7M71.9M3.87M
2026-07-1515.43%11.1M71.9M3.30M
2026-06-3016.02%11.3M70.6M2.72M
2026-06-1517.25%11.1M64.4M2.30M
2026-05-2920.70%12.8M62.0M2.07M
2026-05-1522.16%13.7M62.0M1.83M
2026-04-3019.13%13.1M68.5M1.62M
2026-04-1518.10%12.4M68.5M1.49M
2026-03-3118.91%11.8M62.2M1.47M
2026-03-1317.96%11.2M62.2M1.41M
2026-02-2718.03%11.2M62.2M1.35M
2026-02-1320.25%10.7M52.8M1.41M
2026-01-3016.60%8.8M53.1M1.52M
2026-01-1516.46%8.7M53.1M1.51M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5012.2015.600.000.0000.000.000.993-0.0170.001
call5.009.7013.100.0012.2330.000.000.962-0.0640.002
call7.507.2010.600.008.3640.000.000.942-0.0610.003
call10.004.708.100.005.8570.000.000.914-0.0570.004
call12.502.255.403.293.89220.000.000.866-0.0490.005
call15.000.901.301.070.7432210.000.732-0.0340.008
call17.500.000.500.071.0542070.000.327-0.0560.009
call20.000.000.950.151.0052.000.000.091-0.0230.004
call22.500.002.150.001.3780.000.000.071-0.0260.003
call25.000.002.150.001.6870.000.000.060-0.0280.003
call30.000.002.150.002.1900.000.000.049-0.0310.003
put2.500.000.050.005.7320.000.00-0.007-0.0150.001
put5.000.002.150.005.9240.000.00-0.044-0.0760.002
put7.500.002.150.004.0670.000.00-0.067-0.0730.003
put10.000.000.300.002.5520.000.00-0.085-0.0550.004
put12.500.000.400.071.5934.000.00-0.134-0.0480.005
put15.000.000.300.600.7004780.00-0.268-0.0320.008
put17.500.353.601.852.67944.000.00-0.673-0.0540.009
put20.002.856.100.003.3740.000.00-0.910-0.0210.004
put22.505.408.600.003.9320.000.00-0.929-0.0240.003
put25.007.9011.100.004.3900.000.00-0.940-0.0260.003
put30.0012.9016.100.005.1210.000.00-0.951-0.0280.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-03425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-21DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-21425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-20425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-20SC 13E3/ASEC
2026-10-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-068-KCurrent report2026-10-02SEC
2026-10-02CT ORDERSEC
2026-10-02SC 13E3/ASEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-15425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-31SC 13E3Schedule filed to report going private transactionsSEC
2026-08-208-KCurrent report2026-08-20SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-29SCHEDULE 13GSEC
2026-07-21SCHEDULE 13D/ASEC
2026-07-20425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-07-20425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100462.01K1
2026-100000
2026-0900266.92K4
2026-080000
2026-07003.02M2
2026-06002.54M4
2026-05001.55M3
2026-040000
2026-030000
2026-020000
2026-010013.81K1
2025-12996.11K400
2025-111.74M61.38M2

Institutional holders

Manager% owned
Merck & Co., Inc.13.41%
ARK Investment Management LLC7.90%
BlackRock, Inc.6.76%
Lightspeed Management Company, L.L.C.5.83%
AMERIPRISE FINANCIAL INC5.81%
Deep Track Capital, LP3.82%
Aberdeen Group plc3.26%
VANGUARD CAPITAL MANAGEMENT LLC2.87%
Casdin Capital, LLC2.44%
KENNEDY CAPITAL MANAGEMENT LLC2.26%

Funds

Fund% owned
ARK Genomic Revolution ETF6.31%
abrdn Healthcare Investors2.11%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.05%
iShares Russell 2000 ETF1.65%
abrdn Life Sciences Investors1.47%
Columbia Acorn Fund1.22%
Columbia Small Cap Growth Fund0.88%
VANGUARD EXTENDED MARKET INDEX FUND0.76%
Fidelity Small Cap Index Fund0.70%
iShares Russell 2000 Value ETF0.59%

OakChart. PSNL. Cached 15 minutes.